Prescribing information (external link)
Dermatology insights video hub: watch expert perspectives
Cosentyx® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy.1
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.
Watch leading UK dermatologists share their perspectives on long-term effectiveness and safety profile, real-world evidence, high-impact psoriasis, patient quality of life and the evolving role of Cosentyx in clinical practice.
The evolution of Cosentyx in dermatology: a focus on real-world evidence and safety profile
Prof. Richard Warren, Consultant Dermatologist at The Northern Care Alliance and Professor of Dermatology at the University of Manchester, reflects on the heritage of Cosentyx and its place in modern dermatology practice. In this video, he explores the real-world evidence establishing the long-term effectiveness and safety profile of Cosentyx, including insights from studies such as the SERENA observational study.2
Psoriatic disease in high-impact areas (scalp)
Dr Christos Kasparis, Consultant Dermatologist at Midlands Health UK, reviews the burden of scalp psoriasis and the challenges it can present in clinical practice. In this video, he discusses efficacy data from the scalp study,3 shares insights from real-world patient management, and considers the role of long-term treatment in achieving and maintaining meaningful skin clearance.
Psoriatic disease in high-impact areas (nail)
Dr Christos Kasparis examines nail psoriasis as an important manifestation of psoriatic disease that should not be overlooked. In this video, he reviews efficacy data from the TRANSFIGURE trial,4,5 discusses the association between nail involvement and PsA, and presents a Cosentyx case study of a patient with psoriatic disease around the nail.
Therapeutic indications1
Cosentyx is indicated for the treatment of moderate to severe PsO in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active PsA in adult patients (alone or in combination with MTX) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe HS (acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile PsA in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1
HS, hidradenitis suppurativa; MTX, methotrexate; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, summary of product characteristics.
References
Cosentyx® (secukinumab) Summary of Product Characteristics.
Augustin M, et al. Poster P3355. 33rd European Academy of Dermatology and Venereology Congress. 25–28 September 2024, Amsterdam, the Netherlands.
Bagel J, et al. J Am Acad Dermatol 2017;77(4):667–674.
Reich K, et al. Br J Dermatol 2019;181(5):954–966.
Reich K, et al. Br J Dermatol 2021;184(3):425–436.
UK | October 2026 | FA-11737628
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
